The Feasibility of a Short Bevacizumab Infusion in Patients with Metastatic Colorectal Cancer

被引：0

作者：

Terazawa, Tetsuji ^{[1
,3
]}

Nishitani, Hitoshi ^{[1
,3
]}

Kato, Ken ^{[1
]}

Hashimoto, Hironobu ^{[2
]}

Akiyoshi, Kohei ^{[1
]}

Iwasa, Satoru ^{[1
]}

Nakajima, Takako Eguchi ^{[4
]}

Hamaguchi, Tetsuya ^{[1
]}

Yamada, Yasuhide ^{[1
]}

Shimada, Yasuhiro ^{[1
]}

机构：

[1] Natl Canc Ctr, Gastrointestinal Oncol Div, Chuo Ku, Tokyo 1040045, Japan

[2] Natl Canc Ctr, Dept Pharm, Chuo Ku, Tokyo 1040045, Japan

[3] Osaka Med Coll Hosp, Canc Chemotherapy Ctr, Takatsuki, Osaka, Japan

[4] St Marianna Univ, Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan

来源：

ANTICANCER RESEARCH | 2014年 / 34卷 / 02期

关键词：

Bevacizumab; short infusion; feasibility; FLUOROURACIL; PACLITAXEL; LEUCOVORIN; CARBOPLATIN; ANTIBODY; TRIAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Typically, bevacizumab is initially infused for 90 mm, then for 60 mm, and subsequently for 30 min. The objective of the present study was to evaluate the safety profile of a short infusion of bevacizumab in Japanese colorectal cancer patients. Patients and Methods: The records of 58 patients who received bevacizumab (5 mg/kg) from June 2010 to September 2010 were reviewed. Bevacizumab was administered for 30 min at the first time. If patients had no infusion reaction, the infusion time was shortened to 10 mm. Results: None of the 58 patients who received bevacizumab experienced an infusion reaction (95% confidence interval 0-6.2). The only serious adverse event related to bevacizumab infusion was grade 3 proteinuria in 2 patients. Conclusion: Short infusion of bevacizumab for 30 min the first time and 10 mm is safe and feasible.

引用

页码：1053 / 1056

页数：4

共 24 条

[1]

[Anonymous], 2006, RIT RIT

[2]

[Anonymous], 2006, COMMON TERMINOLOGY C

[3]

[Anonymous], 2006, ERB CET

[4]

[Anonymous], 2005, HERC TRAST

[5] Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis [J].

Botrel, Tobias Engel Ayer ;

Clark, Otavio ;

Clark, Luciana ;

Paladini, Luciano ;

Faleiros, Eneas ;

Pegoretti, Bruna .

LUNG CANCER, 2011, 74 (01) :89-97

[6] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[7] Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer [J].

Cook-Bruns, N .

ONCOLOGY, 2001, 61 :58-66

[8] Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis [J].

Costa Lima, Andre Bacellar ;

Macedo, Ligia T. ;

Sasse, Andre Deeke .

PLOS ONE, 2011, 6 (08)

[9] Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy [J].

Dillman, RO .

CANCER AND METASTASIS REVIEWS, 1999, 18 (04) :465-471

[10] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].

Giantonio, Bruce J. ;

Catalano, Paul J. ;

Meropol, Neal J. ;

O'Dwyer, Peter J. ;

Mitchell, Edith P. ;

Alberts, Steven R. ;

Schwartz, Michael A. ;

Benson, Al B., III .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544

← 1 2 3 →